Boston-based Xellar Biosystems has closed a USD 50 million Series A and A+ financing round to advance its organ-on-chip-based drug discovery platform, which the company describes as a 3D bio intelligence platform combining human tissue models, laboratory automation, and AI-driven biological modeling. The company did not disclose participating investors. Proceeds will be used to expand automated biological data generation, strengthen AI and computational biology capabilities, and advance virtual cell technologies designed to bridge experimental biology and computational modeling.
Founded in 2022 by CEO Xin Xie, Xellar is developing what it describes as a "3D bio intelligence" platform built around a closed-loop system in which organ-on-chip models generate high-dimensional biological data that are analyzed through automated imaging and multi-omics workflows before being used to train AI models. The company argues that the approach addresses a key limitation in AI drug discovery: the lack of scalable, human-relevant datasets capable of supporting predictive biological models.
Earlier this year, Xellar entered a strategic collaboration with South Korea-based WOOJUNG BIO to integrate organ-on-chip and AI technologies for preclinical research. Unlike companies developing therapeutic pipelines, Xellar's business model is focused on providing biological data infrastructure and computational modeling capabilities for biopharmaceutical R&D.